Stockreport

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Prelude Therapeutics Incorporated  (PRLD) 
PDF Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PR [Read more]